Threshold Pharma announces clinical trial date relating to TH-302
Threshold Pharmaceuticals announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented yesterday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 15 to 19 in Boston, MA. In the 401 clinical trial mucosal and skin toxicity were dose-limiting while hematologic toxicity was minimal. :theflyonthewall.com
News For THLD From The Last 14 Days
Check below for free stories on THLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
